In pancreatic cancer, the activation of the JAK/STAT signaling pathway induces the iCAFs phenotype, while JAK inhibitors can transform iCAFs into myCAFs; TGF-β signaling can also antagonize IL1-induced JAK/STAT signaling, thus inhibiting the iCAFs phenotype [60]. This evidence concerns the gene SOAT1 and pancreatic neoplasm.